Friday, 25 May 2018

You are here

Biosimilar Pricing Wars Have Begun

This week Merck announched the US launch of its biosimilar to infliximab, and announced it will discount 35% to the branded version's wholesale acquisition cost. This comes in stark contrast to Pfizer's Inflectra, another infliximab biosimilar, that was lauched with a disappointing 15% discount. Disappointing to those expecting greater savings with biosimilars being newly launched.

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Merck has priced Renflexis at a deeper discount to Remicade (Janssen) and Inflectra (Pfizer). Renflexis will have an introductory wholesale acquisition cost (WAC) of $753.39. The WAC of Remicade was $1,167.82 and Inflectra (infliximab-dyyb) was $946.28 according to Red Book July 24.  WACs do not include discounts that may be paid on the products.

Renflexis was developed by Samsung Bioepis and is being marketed by Merck in the U.S. Renflexis was approved by the FDA on April 21 for the following indications:  Crohn's, pediatric Crohn's disease, rheumatoid arthritis, psorisis, psoriatic arthritis and ankylosing spondylitis.

Sales of Remicade did drop 14% year over year in the second quarter, but J&J chalked much of that decline up to the roughly $170 million in rebate adjustments in the same period last year.

The pricing schemes are unknown for the biosimilars to follow, including Sandoz's Erelzi (etanercept) and Amgen's Amjevita (adalimumab). 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients.